Accelerate to discover

Back to filter

Related topics

Identify the quality of any protein in 3 minutes using microliters of sample with Tycho

NanoTemper

Jul 19, 2019

Tycho tells you so much about the quality of your protein. It tells you about presence, purity, concentration,...

Expanding patient tumor samples has never been so easy - Discover AVATAR

Xcell Biosciences

Jul 10, 2019

The AVATAR Cell Control System lets you fine-tune oxygen and pressure to cater culture conditions to your cell type of...

Take advantage of 4D mode

VisualSonics FujiFilm

Jul 4, 2019

Cutting edgce cardiovascular research demands cutting edge technology. 4D imaging brings together dynamic motion and 3D...

CQ1 confocal quantitative image cytometer: fighting colon cancer with killer cells

Yokogawa

Jul 2, 2019

Genetically modified immune cells can successfully destroy colon cancer cells. This has been demonstrated for the first...

Jul 19, 2019

Assessment of angiotensin II-induced mouse models of abdominal aortic aneurysm

VisualSonics FujiFilm

Jun 28, 2019

Are you working with high ultrasound imaging and are you interesting in progression/ regression of abdominal aortic...

Bionano introduce new SP blood and cell culture DNA isolation kit

BioNano Genomics

Jun 26, 2019

This Bionano prep SP blood and cell culture DNA isolation kit, can provide ultra-high molecular weight (UHMW) gDNA in...

Breast cancer‐derived exosomes reflect the cell of origin phenotype

IZON

Jun 24, 2019

The qNano Gold measures particles using the Tunable Resistive Pulse Sensing (TRPS) principle. TRPS is the most powerful...

Jul 19, 2019

Transcutaneous implantation of valproic acid-encapsulated

Spectral Instruments Imaging

Jun 21, 2019

The interest in alternative material systems and delivery methods for treatment of androgenetic alopecia has been...

Show all topics (10)

Expression profiling of ribosome biogenesis factors in AML patients

Apr 20, 2017

Acute myeloid leukemia (AML) is a heterogeneous disease. Prognosis is mainly influenced by patient age at diagnosis and cytogenetic alterations, two of the main factors currently used in AML patient risk stratification. However, additional criteria are required to improve the current risk classification and better adapt patient care. In neoplastic cells, ribosome biogenesis is increased to sustain the high proliferation rate and ribosome composition is altered to modulate specific gene expression driving tumorigenesis. Here, we investigated the usage of ribosome biogenesis factors as clinical markers in adult patients with AML. We showed that nucleoli, the nucleus compartments where ribosome production takes place, are modified in AML by analyzing a panel of AML and healthy donor cells using immunofluorescence staining. Using four AML series, including the TCGA dataset, altogether representing a total of about 270 samples, we showed that not all factors involved in ribosome biogenesis have clinical values although ribosome biogenesis is increased in AML. Interestingly, we identified the regulator of ribosome production nucleolin (NCL) as over-expressed in AML blasts. Moreover, we found in two series that high NCL mRNA expression level was associated with a poor overall survival, particular in elderly patients. Multivariate analyses taking into account age and cytogenetic risk indicated that NCL expression in blast cells is an independent marker of reduced survival. Our study identifies NCL as a potential novel prognostic factor in AML. Altogether, our results suggest that the ribosome biogenesis pathway may be of interest as clinical markers in AML.

Read more

 

Scientific paper
Application

Get more info

Regina Fillerová

Field application specialist

Regina

Fillerová

+420 731 127 718

Send Message

Brand profile

Fluidigm

Fluidigm is a Molecular and Single Cell Biology company that creates microfluidic-based chips and instrumentation for Life-Science research.

Related products

A new standard for high-throughput real-time PCR, end-point PCR and digital PCR

show detail

We supply and support Life-Science Technologies in the territory of Central and Eastern Europe.

Czech Republic

Slovakia

Hungary

Poland

Croatia

Slovenia

Serbia

Romania

Bulgaria

Latvia

Lithuania

Estonia

Russia

Ukraine

Belarus

Turkey